IN2012DN01322A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01322A
IN2012DN01322A IN1322DEN2012A IN2012DN01322A IN 2012DN01322 A IN2012DN01322 A IN 2012DN01322A IN 1322DEN2012 A IN1322DEN2012 A IN 1322DEN2012A IN 2012DN01322 A IN2012DN01322 A IN 2012DN01322A
Authority
IN
India
Prior art keywords
antibody
cmet
prognosis
disorders associated
relates
Prior art date
Application number
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IN2012DN01322A publication Critical patent/IN2012DN01322A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to an antibody capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for this antibody. The invention likewise comprises the use of said antibody, and corresponding processes, for detecting and diagnosing pathological hyperprol iterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibody for the prognosis or diagnostic of certain cancers.
IN1322DEN2012 2009-08-21 2010-08-23 IN2012DN01322A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25
PCT/EP2010/062271 WO2011020925A1 (en) 2009-08-21 2010-08-23 Anti-cmet antibody and its use for the detection and the diagnosis of cancer

Publications (1)

Publication Number Publication Date
IN2012DN01322A true IN2012DN01322A (en) 2015-06-05

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1322DEN2012 IN2012DN01322A (en) 2009-08-21 2010-08-23

Country Status (19)

Country Link
US (2) US8673302B2 (en)
EP (2) EP2287197A1 (en)
JP (1) JP5951486B2 (en)
KR (1) KR20120051734A (en)
CN (1) CN102639564B (en)
AR (1) AR077901A1 (en)
AU (1) AU2010284944B2 (en)
BR (1) BR112012003759A2 (en)
CA (1) CA2769427C (en)
ES (1) ES2692522T3 (en)
IL (1) IL218202A (en)
IN (1) IN2012DN01322A (en)
MX (1) MX2012002139A (en)
NZ (2) NZ700437A (en)
RU (1) RU2582265C2 (en)
SG (1) SG178339A1 (en)
TW (1) TW201111781A (en)
WO (1) WO2011020925A1 (en)
ZA (1) ZA201202076B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
JP2013537966A (en) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド Biomarkers and methods of treatment
KR101444837B1 (en) 2011-06-03 2014-09-30 한국생명공학연구원 c-Met-targeting full agonist human antibody with HGF activity and usage thereof
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
KR20130036993A (en) * 2011-10-05 2013-04-15 삼성전자주식회사 Antibodies specifically binding to epitope in sema domain of c-met
CN104066748A (en) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 Purification of anti-c-met antibodies
WO2013078145A1 (en) * 2011-11-21 2013-05-30 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of hec1 activity
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2013169532A1 (en) * 2012-05-09 2013-11-14 Eli Lilly And Company Anti-c-met antibodies
CN105050618B (en) * 2012-06-21 2018-11-16 索伦托治疗有限公司 Antigen-binding proteins in conjunction with c-Met
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
JP2017516458A (en) * 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
JP2017524371A (en) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド MIT biomarkers and methods of use
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
CN107531780B (en) * 2015-02-03 2021-11-02 国家健康与医学研究院 Conformational single domain antibodies to Rho GTPase and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10722592B2 (en) * 2015-03-18 2020-07-28 Seattle Genetics, Inc. CD48 antibodies and conjugates thereof
EP3411067B1 (en) * 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
RS60663B1 (en) 2016-05-17 2020-09-30 Abbvie Biotherapeutics Inc Anti-cmet antibody drug conjugates and methods for their use
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
RU2735918C2 (en) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Reagent kit for detecting a marker of epithelial carcinomas
EP3816186A4 (en) * 2018-06-29 2022-04-06 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Pd-l1-binding polypeptide and use thereof
KR102396194B1 (en) * 2018-12-07 2022-05-10 서울대학교 산학협력단 Anti c-Met agonist antibody and uses thereof
EP3980783A4 (en) * 2019-06-06 2023-09-13 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
KR20230018454A (en) 2020-09-01 2023-02-07 레메젠 코, 리미티드 Anti-c-Met Antibody-Drug Conjugates and Uses Thereof
JP2023541011A (en) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド Pharmaceutical combinations and tumor treatment
WO2023240272A2 (en) * 2022-06-09 2023-12-14 Santa Ana Bio, Inc. Antibodies targeting c-kit and/or siglec and uses thereof
WO2024030341A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
EP1516185A4 (en) * 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
DK1981981T3 (en) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoclonal anti-met antibody, fragments and vectors thereof for the treatment of tumors, and similar products
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (en) * 2008-12-02 2011-01-19 Pf Medicament ANTI-CMET ANTIBODY (C-MET RECEIVER)
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
MX2012002139A (en) 2012-03-07
SG178339A1 (en) 2012-03-29
EP2467402A1 (en) 2012-06-27
WO2011020925A1 (en) 2011-02-24
AR077901A1 (en) 2011-09-28
NZ700437A (en) 2016-04-29
US8673302B2 (en) 2014-03-18
EP2467402B1 (en) 2018-08-01
ZA201202076B (en) 2012-11-28
EP2287197A1 (en) 2011-02-23
JP5951486B2 (en) 2016-07-13
US20120149031A1 (en) 2012-06-14
US20140295452A1 (en) 2014-10-02
CA2769427C (en) 2020-03-10
IL218202A (en) 2017-07-31
BR112012003759A2 (en) 2017-07-11
AU2010284944A1 (en) 2012-03-08
AU2010284944B2 (en) 2016-01-28
KR20120051734A (en) 2012-05-22
CN102639564A (en) 2012-08-15
ES2692522T3 (en) 2018-12-04
IL218202A0 (en) 2012-04-30
CA2769427A1 (en) 2011-02-24
TW201111781A (en) 2011-04-01
JP2013502213A (en) 2013-01-24
CN102639564B (en) 2015-01-07
RU2582265C2 (en) 2016-04-20
NZ598194A (en) 2015-05-29
RU2012109004A (en) 2013-09-27

Similar Documents

Publication Publication Date Title
IN2012DN01322A (en)
MX2012014739A (en) Novel antibody for the diagnosis and/or prognosis of cancer.
ATE551073T1 (en) LABELED HGF-BINDING PEPTIDES FOR IMAGING
GB0718967D0 (en) Peptide imaging agents
BR112012007365A2 (en) il-1 binding proteins
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX2008009886A (en) Antibodies that bind par-2.
MX2010000405A (en) Drug selection for lung cancer therapy using antibody-based arrays.
IL207637A (en) Drug selection for breast cancer therapy using antibody-based arrays
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2010140834A3 (en) Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
EP2585826A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
GB0815846D0 (en) diagnosis, prognosis and imaging of disease
EP2081029A3 (en) Bio-markers for diagnosing diabetic retinopathy
WO2014117680A3 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia
WO2013063412A3 (en) Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
NZ707637A (en) Signal biomarkers
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
WO2010122135A3 (en) Use of mixed lineage like kinase polypeptides (mlkl polypeptides) in cancer therapy
MX349494B (en) Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers.